SIGNATURES ON THE FOLLOWING PAGE Clause Samples
The 'Signatures on the Following Page' clause indicates that the signature blocks for the parties to the agreement are not located on the same page as the main body of the contract, but instead appear on a subsequent page. In practice, this clause is typically placed at the end of the contract text, just before a page break, to direct the reader to where the parties will sign. Its core function is to ensure clarity and proper execution of the agreement by clearly identifying where the parties should sign, especially in multi-page documents.
POPULAR SAMPLE Copied 3 times
SIGNATURES ON THE FOLLOWING PAGE. The person signing below on behalf of TWU and the Performer or Agent warrants that he/she has the authority to execute this Agreement according to its terms.
SIGNATURES ON THE FOLLOWING PAGE. I certify under penalty of perjury that the above information is true and correct and that Sponsor shall comply with all requirements set forth above, in Sponsor's Certification No. 10, Construction Drawings for First Submittal To Building Department as a condition of receiving the Program Funds. Authorized Signature Typed Name of Signatory Title of Signatory Date Authorized Signature Typed Name of Signatory Title of Signatory Date
SIGNATURES ON THE FOLLOWING PAGE. The covenants herein contained shall, except as otherwise provided, accrue to the benefit of and be binding upon the successors and assigns of the Parties hereto.
SIGNATURES ON THE FOLLOWING PAGE. Grantor hereby binds itself and its successors and assigns to warrant and defend the title to the Property against the acts of Grantor and no other. DATED as of , 20 . GRANTOR: CITY OF ▇▇▇▇▇▇▇▇, an Arizona municipal corporation By: Name: Its: ATTEST: CITY CLERK APPROVED AS TO FORM: CITY ATTORNEY STATE OF ARIZONA ) ) ss. County of Maricopa ) The foregoing Agreement was acknowledged before me this day of , 20 , by Notary Public My Commission Expires: To inform [VPK The Row, LLC, an Arizona limited liability company] ("Transferee"), that withholding of tax under Section 1445 of the Internal Revenue Code of 1986, as amended ("Code") will not be required by City of ▇▇▇▇▇▇▇▇, an Arizona municipal corporation ("Transferor"), who hereby certifies the following:
SIGNATURES ON THE FOLLOWING PAGE. I further AFFIRM AND ACKNOWLEDGE that I consent to join and opt-in to become a plaintiff for settlement purposes in the Litigation against Equitable, and to be subject to the release set forth in Section IV (“Release”) of the Parties’ Settlement Agreement.
SIGNATURES ON THE FOLLOWING PAGE. To show their agreement, authorized representatives of the parties have signed duplicate counterparts below. THE CHANCELLOR, MASTERS AND MEMORIAL ▇▇▇▇▇ SCHOLARS OF THE KETTERING OF THE UNIVERISTY OF CAMBRIDGE CANCER CENTER /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, MD ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, MD Vice President Technology Development Date: Jan 7, 2019 By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ Title: Senior Contracts Manager Date: 10-1-18 I, the undersigned Project Manager will use reasonable efforts to uphold my obligations and responsibilities set forth in this Agreement. I, the undersigned Project Manager will use reasonable efforts to uphold my obligations and responsibilities set forth in this Agreement. By: /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ By: /s/ ▇▇▇▇ ▇▇▇▇▇▇ Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ Name: ▇▇▇▇ ▇▇▇▇▇▇ Date: 17/1/2019 Date: Jan 7, 2019 By: /s/ ▇▇. ▇▇▇▇ ▇▇▇▇▇▇ Name: ▇▇. ▇▇▇▇ ▇▇▇▇▇▇ Title: CEO Date: 3/1/19 I, the undersigned Project Manager will use reasonable efforts to uphold my obligations and responsibilities set forth in this Agreement. By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇ Tuff Name: ▇▇▇▇▇ ▇▇▇▇▇▇ Tuff Title: Director of Clinical Affairs and Medical Education cambridge shall provide the algorithm and related information to Phenogen to enable Phenogen to generate ‘Polygenic Risk Scores for BRCAl and BRCA2 mutation carriers. Phenogen shall provide the Polygenic Risk Scores to MSKCC to enable the MSKCC Scientist to apply those as part of a research project which will aim to provide more personalised cancer risks for women with BRCAl and BRCAZ mutations and which will allow for informed decisions about the clinical management of women with BRCA1/2 mutations. All results shall be shared with Cambridge for research purposes. Deliverables from Study-MSl(CC
SIGNATURES ON THE FOLLOWING PAGE. This Agreement is executed by the Company on this ___ day of __________, 20__.